WhatsApp

Two Drug Combo Slows Ovarian Cancer Return—But Only for Some

You are here >> Home > Latest Updates > Ovarian Cancer > Two Drug…

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer DOI 10.3322caac.70042

Doctors tested a new mix of medicines to help stop advanced ovarian cancer from coming back. The study looked at whether combining fuzuloparib with apatinib worked better than using fuzuloparib alone.

Fuzuloparib is a drug that helps cancer cells stop repairing themselves. Apatinib works by cutting off blood supply to the tumor. Both were given after standard chemotherapy to keep the cancer from returning.

Nearly 700 women joined the study. Some got both drugs, some got fuzuloparib alone, and others got placebo (no real drug). Women who got either fuzuloparib or the combo stayed cancer-free longer—about 27 to 30 months—compared to only 11 months for those who got no drug.

In women with certain genetic traits (called HRD, including BRCA mutations), both treatments worked about the same. In women without those traits, the combo had a small edge.

There were no new safety concerns. All the treatments were handled well by patients.

This study shows that maintenance therapy with fuzuloparib, with or without apatinib, helps delay the return of ovarian cancer. The extra benefit of combining drugs may depend on your cancer type.

Ask your doctor if these treatments are right for your kind of ovarian cancer.

Rate this post
dr swati shah - uro & gynec cancer surgeon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.